Randomised Phase II Pilot Study: Induction Chemotherapy with Docetaxel, Cisplatin and Cetuximab versus Docetaxel, Cisplatin and 5 FU followed by Radiotherapy with Cetuximab for locally advanced or not resectable Carcinoma of the Head and Neck [Randomisierte Phase II Pilot Studie: Induktionstherapie mit Docetaxel, Cisplatin und Cetuximab versus Docetaxel, Cisplatin und 5 FU gefolgt von Radioimmuntherapie mit Cetuximab bei lokal fortgeschrittenen oder inoperablen HNO Tumoren]

Trial Profile

Randomised Phase II Pilot Study: Induction Chemotherapy with Docetaxel, Cisplatin and Cetuximab versus Docetaxel, Cisplatin and 5 FU followed by Radiotherapy with Cetuximab for locally advanced or not resectable Carcinoma of the Head and Neck [Randomisierte Phase II Pilot Studie: Induktionstherapie mit Docetaxel, Cisplatin und Cetuximab versus Docetaxel, Cisplatin und 5 FU gefolgt von Radioimmuntherapie mit Cetuximab bei lokal fortgeschrittenen oder inoperablen HNO Tumoren]

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Docetaxel; Fluorouracil
  • Indications Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top